iPharmaCenter

#CHMP gave a positive opinion for treating BMS' cell-therapy #Breyanzi for relapsed or refractory #follicularlymphoma https://www.ipharmacenter.com/post/european-drug-approvals-chmp-positive-opinions-january-2025-ipharmacenter #pharma #pharmaceutical #Science #breaking #breakingnews #news #media #medicine #Europe #healthcare #MedComms #MedicalAffairs #Medical

#Imfinzi is recommended for approval in #Europe for adult patients with limited-stage small cell #lungcancer https://www.ipharmacenter.com/post/european-drug-approvals-chmp-positive-opinions-january-2025-ipharmacenter #pharma #pharmaceutical #Science #breaking #breakingnews #news #media #medicine #Europe #healthcare #MedComms #MedicalAffairs #Medical

#BMS' #Opdivo plus #Yervoy combination was approved as 1L treatment for adult patients with unresectable or advanced HCC https://www.ipharmacenter.com/post/european-drug-approvals-chmp-positive-opinions-january-2025-ipharmacenter #pharma #pharmaceutical #Science #breaking #breakingnews #news #media #medicine #Europe #healthcare #MedComms #MedicalAffairs #Medical

#AstraZeneca's ADC #Enhertu is now approved in #US for HR-positive, HER2-low or ultra low #breastcancer https://www.ipharmacenter.com/post/astrazeneca-s-adc-enhertu-is-now-approved-in-us-for-hr-postive-her2-low-or-ultralow-breast-cancer #pharma #pharmaceutical #Science #news #media #medicine #USA #USNews #healthcare #MedComms #MedicalAffairs #Medical #Trump #PresidentTrump

#NICE recommended use of #Vertex's £1.6m SCD curative #genetherapy, #Casgevy https://www.ipharmacenter.com/post/nice-recommended-use-of-vertex-s-1-6m-scd-curative-gene-therapy-casgevy-ipharmacenter #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #NICENews #NICE #England #UnitedKingdom #marketaccess #globalhealth #London #PMStarmer #Starmer

#AstraZeneca delivered impressive financial results for 2024, reporting a 21% increase in total revenue, reaching $54.1 billion. https://www.ipharmacenter.com/post/top-pharmaceutical-companies-by-revenues-in-2024 #AZN #breaking #BreakingNews #Revenues #pharmaceuticals #science #news #media #medicine #Europe #patientcare #news

#Pfizer’s #Talzenna Combined with #Xtandi Shows Significant Survival Benefits in Metastatic Castration-Resistant #ProstateCancer https://www.ipharmacenter.com/post/american-society-of-clinical-oncology-genitourinary-cancers-symposium-asco-gu-2025-in-san-francisc #pharma #pharmaceutical #Science #ASCOGU25 #GU25 #news #media #medicine #OncoTwitter #MedicalAffairs #Medical #PatientSafety

Winter Clinical Dermatology Conference - Five-Year Data Confirms Safety & Long-Term Efficacy of TYK2 Inhibitor for Plaque #Psoriasis https://www.ipharmacenter.com/post/winter-clinical-dermatology-conference-hawaii-wch-2025-ipharmacenter #WCH2025 #BMSNews #BMS #OneBMS #dermatology #health #breaking #breakingnews #news #healthcare #HealthForAll #WCH25 #WCH2025